Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Acton Pharmaceuticals, Inc. to be Acquired by Meda for up to $200 Million

Published: Friday, September 06, 2013
Last Updated: Friday, September 06, 2013
Bookmark and Share
Acton Pharmaceuticals, Inc. announced that it has entered into a definitive agreement under which the Company will be acquired by Meda in an all cash transaction.

The proposed transaction is subject to customary regulatory approvals and standard closing provisions.

Under the terms of the agreement, Meda will acquire 100% of Acton’s shares for $135 million plus $10 million in a contingent, near-term development milestone.  Acton will also receive certain sales-based milestones, which may bring the total potential acquisition value up to $200 million.

Acton is focused on the development of respiratory medicine and recently received U.S. Food and Drug Administration approval for AEROSPAN™ (flunisolide), for the treatment of asthma. AEROSPAN is a HFA-propelled inhaled corticosteroid (ICS) and is the only approved HFA inhaler in its class to incorporate a built-in spacer device, which assists in the delivery of the medicine to the lungs.  The value of the U.S. single-entity ICS market is approaching $2 billion with more than 12 million prescriptions written each year.
AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older.

Acton was founded in March 2008 by John Simon, Chief Executive Officer and Daniel Kreisler, President & Chief Operating Officer of Acton.

"Through this transaction with Meda, AEROSPAN will now be commercialized by a company with one of the leading respiratory focused sales forces in the U.S.,” commented Daniel Kreisler.  “We strongly believe this will accelerate the prescribing of this unique inhaled steroid product so we can achieve our goal of making AEROSPAN one of the leading therapies in the $2 billion U.S. inhaled steroid market.”

John Simon continued, “We are excited to enter into this agreement with Meda, a leading global pharmaceutical company.  Meda’s experience marketing respiratory products combined with their significant track record of success makes them extremely well-suited to launch AEROSPAN to respiratory and pediatric physicians in the U.S.”

Scott Carter, a partner at Sequoia Capital and a member of Acton’s Board of Directors said, “We are very fortunate to partner with Acton Pharmaceuticals.  Sequoia Capital recognizes and applauds the excellence of this highly experienced management team who has driven the company to tremendous success.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Smart Gloves Monitor Parkinson’s Disease
URI biomedical engineering professor creating smart gloves to monitor parkinson’s disease patients.
Zika Virus Infection Alters Human and Viral RNA
Researchers have discovered that Zika infections results in human and viral genetic modification.
Cell Metabolism Linked to Spread of Cancer
Scientists discover macrophage metabolism can be attuned to prevent the spread of cancer.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Advances in Alzheimer’s Research
Researchers show how a diseased vertebrate brain can naturally react to Alzheimer’s pathology by forming more neurons.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos